2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was RMB 575,002,491.20, representing a year-on-year increase of 15.11%[8] - The net profit attributable to shareholders for Q3 2023 was RMB 236,971,204.96, a decrease of 9.18% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 234,201,796.98, down 10.04% year-on-year[8] - The comprehensive income total for Q3 2023 was RMB 336,381,200.67, compared to RMB 666,161,460.87 in the same period last year[25] - Operating revenue for Q3 2023 reached ¥1,587,079,779.38, an increase from ¥1,276,392,981.45 in Q3 2022, representing a growth of approximately 24.4%[52] - Operating profit for Q3 2023 was ¥392,084,940.00, a decrease from ¥717,775,641.91 in the same period last year, showing a decline of about 45.4%[53] Assets and Liabilities - The company's total assets at the end of Q3 2023 were RMB 10,232,670,064.53, a decrease of 1.27% from the end of the previous year[7] - As of September 30, 2023, the total current assets amounted to approximately RMB 7.25 billion, an increase from RMB 5.93 billion at the end of 2022, reflecting a growth of 22.3%[44] - The total liabilities decreased to approximately RMB 1.99 billion from RMB 2.17 billion at the end of 2022, indicating a reduction of about 8.2%[49] - The total assets as of September 30, 2023, were approximately RMB 10.23 billion, a slight decrease from RMB 10.36 billion at the end of 2022[49] - The company's equity attributable to shareholders increased to approximately RMB 8.23 billion from RMB 8.18 billion at the end of 2022, showing a growth of about 0.6%[49] Cash Flow - The net cash flow from operating activities for Q3 2023 was RMB 448,440,218.42, a decrease of 42.38%[7] - The net cash flow from operating activities for the first three quarters of 2023 was ¥448,440,218.42, a decrease of 42.38% compared to ¥778,288,380.46 in the same period of 2022[30] - The total cash inflow from operating activities was ¥1,874,131,001.01, down from ¥2,085,281,684.08 in the previous year, reflecting a decline of approximately 10.13%[30] - The total cash outflow from operating activities was ¥1,425,690,782.59, compared to ¥1,306,993,303.62 in the previous year, indicating an increase of approximately 9.05%[30] - The company experienced a decrease in cash received from investment activities, totaling ¥528,639,464.14, down from ¥788,066,438.90 in the previous year[30] - The company's financing activities resulted in a net cash outflow of -¥333,289,197.75, compared to -¥86,387,525.79 in the same period last year[30] Profitability and Expenses - The weighted average return on equity for Q3 2023 was 2.88%, a decrease of 4.51% compared to the same period last year[7] - Total operating costs amounted to ¥1,104,837,171.01, up from ¥810,012,663.71, indicating a rise of about 36.3%[53] - Research and development expenses increased to ¥77,639,680.27 from ¥50,053,890.87, reflecting a growth of approximately 55.2%[53] - Other income for the quarter was ¥235,928.52, significantly lower than ¥14,635,576.11 in Q3 2022, indicating a decrease of approximately 98.4%[53] - The fair value change loss was ¥-108,513,934.09, contrasting with a gain of ¥235,768,268.74 in the previous year, marking a significant shift[53] - The company reported a net credit impairment loss of ¥-3,187,147.18, down from ¥-4,597,870.22, indicating an improvement in credit quality[53] Business Operations - The laboratory services business contributed a net profit of RMB 30,886.27 million, showing a growth of 16.03% year-on-year[10] - The financial management income contributed RMB 10,307.35 million to net profit[10] - The fair value changes of biological assets resulted in a net loss of RMB 10,084.80 million[10] - The company plans to focus on expanding its market presence and developing new products in response to the current industry challenges[40] - The company plans to focus on market expansion and new product development in the upcoming quarters[52] - The group signed new orders amounting to approximately RMB 1.8 billion during the reporting period, with a total backlog of approximately RMB 3.66 billion as of the end of the reporting period[40] Shareholder Information - The total number of common shareholders at the end of the reporting period was 56,937, indicating a diverse shareholder base[36] - The basic earnings per share decreased by 47.62% year-on-year, reflecting the impact of fair value losses on biological assets[33] - The cash and cash equivalents at the end of the period were ¥2,891,274,796.93, slightly down from ¥2,899,469,580.53 at the beginning of the period[32] - The inventory as of September 30, 2023, was approximately RMB 2.12 billion, down from RMB 2.19 billion at the end of 2022, reflecting a decrease of about 3.3%[44] - The company reported a decrease in accounts payable to approximately RMB 67.95 million from RMB 127.31 million at the end of 2022, a reduction of about 46.5%[49] - The company has not classified any non-recurring gains and losses as regular gains and losses, confirming adherence to regulatory definitions[50]